Todd Fraser, MD, speaks with Rinaldo Bellomo, MD, MBBS, FRACP, FCICM, FAAHMS, about the article "Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II" (Tumlin JA, et al. Crit Care Med. 2018;46:949-957).
Dr. Bellomo discusses his post-talk analysis of the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) trial and potential benefits of angiotensin II in patients with shock requiring renal replacement therapy. Dr. Bellomo is the director of intensive care research at Austin Hospital in Melbourne, Australia.
